Clinical Trials Logo

Clinical Trial Summary

L-theanine and caffeine are two natural constituents of tea. Both of these compounds are among the U.S. Food and Drug Administration's list of Generally Recognized as Safe (GRAS) substances. Results of several clinical trials the PI and his team has conducted are consistent with results of many others to indicate that oral intake of each of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine is associated with improved attention in adults. Furthermore, there is evidence to suggest that, when taken in combination, L-theanine and caffeine seem to have additive effects in improving attention in adults. However, the specific actions of these substances have not been examined in children and adolescents with attention deficit hyperactivity disorder (ADHD), who are characterized by impaired attention, hyperkinesia and impulsivity.

Therefore, the investigators plan to study the functional activity of brains (both at rest and when performing standard tasks designed to measure attention) in children diagnosed with ADHD using functional magnetic resonance imaging, after they consume either 2.5 mg/kg of L-theanine, 2.0 mg/kg of caffeine and their combination as compared to a placebo (water). Based on our previous findings, the investigators expect to observe improvements (speed of responding and accuracy) in standard tests of attention with intake of L-theanine, caffeine and their combination as compared to the placebo. The investigators also expect to observe decreased functional activity in brain regions that typically show increased activity during mind wandering with intake of L-theanine, caffeine and their combination.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder
  • Disease
  • Hyperkinesis

NCT number NCT03533556
Study type Interventional
Source Texas Tech University
Contact
Status Completed
Phase Early Phase 1
Start date May 14, 2018
Completion date August 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06129396 - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT04779333 - Lifestyle Enhancement for ADHD Program 2 N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Completed NCT04832737 - Strength-based Treatment Approach for Adults With ADHD N/A
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Recruiting NCT05048043 - Development of a Game-supported Intervention N/A
Completed NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Not yet recruiting NCT06454604 - Virtual Reality Treatment for Emerging Adults With ADHD Phase 2
Not yet recruiting NCT06406309 - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD N/A
Not yet recruiting NCT06080373 - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial N/A
Completed NCT02477280 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance Phase 4
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02555150 - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD Phase 3
Completed NCT02390791 - New Technologies to Help Manage ADHD N/A
Completed NCT02780102 - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD N/A
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02473185 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest Phase 4
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Recruiting NCT04175028 - Neuromodulation of Executive Function in the ADHD Brain N/A